;PMID: 9855271 ;source_file_1380.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..43] = [t:0..43] ;1)sentence:[e:48..166] = [t:48..166] ;2)section:[e:170..272] = [t:170..272] ;3)section:[e:276..358] = [t:276..358] ;4)sentence:[e:362..441] = [t:362..441] ;5)sentence:[e:443..619] = [t:443..619] ;6)sentence:[e:620..788] = [t:620..788] ;7)sentence:[e:789..931] = [t:789..931] ;8)sentence:[e:932..1088] = [t:932..1088] ;9)sentence:[e:1089..1195] = [t:1089..1195] ;10)sentence:[e:1196..1286] = [t:1196..1286] ;11)sentence:[e:1287..1400] = [t:1287..1400] ;12)sentence:[e:1401..1502] = [t:1401..1502] ;13)section:[e:1506..1550] = [t:1506..1550] ;section 0 Span:0..43 ;J Clin Gastroenterol 1998 Dec;27(4):357-60 (SEC (FRAG (NNP:[0..1] J) (DT:[2..6] Clin) (NNP:[7..20] Gastroenterol) (CD:[22..26] 1998) (.:[27..34] Dec;27-LRB-) (CD:[34..36] 4-RRB-) (CD:[36..40] :357) (HYPH:[40..41] -) (CD:[41..43] 60))) ;sentence 1 Span:48..166 ;Pancreatic cancer associated with granulocyte-colony stimulating factor ;production confirmed by immunohistochemistry. ;[48..65]:malignancy:"Pancreatic cancer" ;[82..119]:gene-protein:"granulocyte-colony stimulating factor" (SENT (NP-HLN (NP (NP (JJ:[48..58] Pancreatic) (NN:[59..65] cancer)) (VP (VBN:[66..76] associated) (NP (-NONE-:[76..76] *)) (PP-CLR (IN:[77..81] with) (NP (NML (NML (NML (NN:[82..93] granulocyte) (HYPH:[93..94] -) (NN:[94..100] colony)) (VBG:[101..112] stimulating)) (NN:[113..119] factor)) (NN:[121..131] production))))) (VP (VBN:[132..141] confirmed) (NP (-NONE-:[141..141] *)) (PP-MNR (IN:[142..144] by) (NP (NN:[145..165] immunohistochemistry)))) (.:[165..166] .))) ;section 2 Span:170..272 ;Ohtsubo K, Mouri H, Sakai J, Akasofu M, Yamaguchi Y, Watanabe H, Gabata T, ;Motoo Y, Okai T, Sawabu N. (SEC (FRAG (NNP:[170..177] Ohtsubo) (NNP:[178..179] K) (,:[179..180] ,) (NNP:[181..186] Mouri) (NNP:[187..188] H) (,:[188..189] ,) (NNP:[190..195] Sakai) (NNP:[196..198] J,) (NNP:[199..206] Akasofu) (NNP:[207..209] M,) (NNP:[210..219] Yamaguchi) (NNP:[220..221] Y) (,:[221..222] ,) (NNP:[223..231] Watanabe) (NNP:[232..233] H) (VBD:[233..234] ,) (NNP:[235..241] Gabata) (NNP:[242..243] T) (,:[243..244] ,) (NNP:[245..250] Motoo) (NNP:[252..253] Y) (VBD:[253..254] ,) (NNP:[255..259] Okai) (NNP:[260..261] T) (,:[261..262] ,) (NNP:[263..269] Sawabu) (NNP:[270..272] N.))) ;section 3 Span:276..358 ;Department of Internal Medicine and Medical Oncology, Kanazawa University, ;Japan. (SEC (FRAG (NNP:[276..286] Department) (IN:[287..289] of) (NNP:[290..298] Internal) (NNP:[299..307] Medicine) (CC:[308..311] and) (NNP:[312..319] Medical) (NNP:[320..328] Oncology) (,:[328..329] ,) (NNP:[330..338] Kanazawa) (NNP:[339..349] University) (,:[349..350] ,) (NNP:[352..357] Japan) (.:[357..358] .))) ;sentence 4 Span:362..441 ;We report an 83-year-old man with pancreatic body cancer of 4.5 cm in ;diameter. ;[396..440]:malignancy:"pancreatic body cancer of 4.5 cm in diameter" (SENT (S (NP-SBJ (PRP:[362..364] We)) (VP (VBP:[365..371] report) (NP (NP (DT:[372..374] an) (ADJP (NML (CD:[375..377] 83) (HYPH:[377..378] -) (NN:[378..382] year)) (HYPH:[382..383] -) (JJ:[383..386] old)) (NN:[387..390] man)) (PP (IN:[391..395] with) (NP (NP (JJ:[396..406] pancreatic) (NN:[407..411] body) (NN:[412..418] cancer)) (PP (IN:[419..421] of) (NP (NP (CD:[422..425] 4.5) (NN:[426..428] cm)) (PP (IN:[429..431] in) (NP (NN:[432..440] diameter))))))))) (.:[440..441] .))) ;sentence 5 Span:443..619 ;Peripheral leukocyte count was 15,700/microl and the serum concentration of ;granulocyte-colony stimulating factor (G-CSF) was 123 pg/ml (normal, 6.0-21.9 ; pg/ml) on admission. ;[520..557]:gene-protein:"granulocyte-colony stimulating factor" ;[559..564]:gene-protein:"G-CSF" (SENT (S (S (NP-SBJ (JJ:[443..453] Peripheral) (NN:[454..463] leukocyte) (NN:[464..469] count)) (VP (VBD:[470..473] was) (NP-PRD (NP (CD:[474..480] 15,700)) (PP (SYM:[480..481] /) (NP (NN:[481..487] microl)))))) (CC:[488..491] and) (S (NP-SBJ (NP (DT:[492..495] the) (NN:[496..501] serum) (NN:[502..515] concentration)) (PP (IN:[516..518] of) (NP (NP (NML (NML (NN:[520..531] granulocyte) (HYPH:[531..532] -) (NN:[532..538] colony)) (VBG:[539..550] stimulating)) (NN:[551..557] factor)) (NP (-LRB-:[558..559] -LRB-) (NN:[559..564] G-CSF) (-RRB-:[564..565] -RRB-))))) (VP (VBD:[566..569] was) (NP-PRD (NP (CD:[570..573] 123) (NN:[574..576] pg)) (PP (SYM:[576..577] /) (NP (NN:[577..579] ml)))) (PRN (-LRB-:[580..581] -LRB-) (S (NP-SBJ (JJ:[581..587] normal)) (,:[587..588] ,) (NP-PRD (NP (QP (CD:[589..592] 6.0) (HYPH:[592..593] -) (CD:[593..597] 21.9)) (NN:[599..601] pg)) (PP (SYM:[601..602] /) (NP (NN:[602..604] ml))))) (-RRB-:[604..605] -RRB-)) (PP (IN:[606..608] on) (NP (NN:[609..618] admission))))) (.:[618..619] .))) ;sentence 6 Span:620..788 ;Furthermore, not only K-ras codon 12 (GGT --> GAT) but also p53 at codon 247 ;(CGG --> CCG) mutations were identified in the pancreatic juice aspirated ;endoscopically. ;[642..647]:gene-rna:"K-ras" ;[648..656]:variation-location:"codon 12" ;[658..661]:variation-state-original:"GGT" ;[666..669]:variation-state-altered:"GAT" ;[681..684]:gene-rna:"p53" ;[688..697]:variation-location:"codon 247" ;[699..702]:variation-state-original:"CGG" ;[707..710]:variation-state-altered:"CCG" ;[712..721]:variation-event:"mutations" (SENT (S (ADVP (RB:[620..631] Furthermore)) (,:[631..632] ,) (NP-SBJ-2 (CONJP (RB:[633..636] not) (RB:[637..641] only)) (NP (NN:[642..647] K-ras) (NML (NN:[648..653] codon) (CD:[654..656] 12)) (NML-1 (-NONE-:[656..656] *P*)) (PRN (-LRB-:[657..658] -LRB-) (NP (NP (NN:[658..661] GGT)) (PP (SYM:[662..665] -->) (NP (NN:[666..669] GAT)))) (-RRB-:[669..670] -RRB-))) (CONJP (CC:[671..674] but) (RB:[675..679] also)) (NP (NP (NN:[681..684] p53)) (PP-LOC (IN:[685..687] at) (NP (NML (NN:[688..693] codon) (CD:[694..697] 247)) (PRN (-LRB-:[698..699] -LRB-) (NP (NP (NN:[699..702] CGG)) (PP (SYM:[703..706] -->) (NP (NN:[707..710] CCG)))) (-RRB-:[710..711] -RRB-)) (NML-1 (NNS:[712..721] mutations)))))) (VP (VBD:[722..726] were) (VP (VBN:[727..737] identified) (NP-2 (-NONE-:[737..737] *)) (PP-LOC (IN:[738..740] in) (NP (NP (DT:[741..744] the) (JJ:[745..755] pancreatic) (NN:[756..761] juice)) (VP (VBN:[763..772] aspirated) (NP (-NONE-:[772..772] *)) (ADVP-MNR (RB:[773..787] endoscopically))))))) (.:[787..788] .))) ;sentence 7 Span:789..931 ;We performed chemotherapy with two courses of 5-fluorouracil, pirarubicin ;hydrochloride, and mitomycin-C, resulting in no beneficial effect. (SENT (S (NP-SBJ (PRP:[789..791] We)) (VP (VBD:[792..801] performed) (NP (NN:[802..814] chemotherapy)) (PP-MNR (IN:[815..819] with) (NP (NP (CD:[820..823] two) (NNS:[824..831] courses)) (PP (IN:[832..834] of) (NP (NP (NN:[836..850] 5-fluorouracil)) (,:[850..851] ,) (NP (NN:[852..863] pirarubicin) (NN:[864..877] hydrochloride)) (,:[877..878] ,) (CC:[879..882] and) (NP (NN:[883..894] mitomycin-C)))))) (,:[894..895] ,) (S-ADV (NP-SBJ (-NONE-:[895..895] *)) (VP (VBG:[896..905] resulting) (PP-CLR (IN:[906..908] in) (NP (DT:[909..911] no) (JJ:[913..923] beneficial) (NN:[924..930] effect)))))) (.:[930..931] .))) ;sentence 8 Span:932..1088 ;After the second course the patient developed interstitial pneumonia, ;probably caused by anticancer drugs, and died 4 months after the tumor was ;detected. ;[1069..1074]:malignancy:"tumor" (SENT (S (PP-TMP (IN:[932..937] After) (NP (DT:[938..941] the) (JJ:[942..948] second) (NN:[949..955] course))) (NP-SBJ (DT:[956..959] the) (NN:[960..967] patient)) (VP (VP (VBD:[968..977] developed) (NP (NP (JJ:[978..990] interstitial) (NN:[992..1001] pneumonia)) (,:[1001..1002] ,) (VP (ADVP (RB:[1003..1011] probably)) (VBN:[1012..1018] caused) (NP (-NONE-:[1018..1018] *)) (PP (IN:[1019..1021] by) (NP-LGS (JJ:[1022..1032] anticancer) (NNS:[1033..1038] drugs)))))) (,:[1038..1039] ,) (CC:[1040..1043] and) (VP (VBD:[1044..1048] died) (NP-TMP (NP (CD:[1049..1050] 4) (NNS:[1051..1057] months)) (PP (IN:[1058..1063] after) (S-NOM (NP-SBJ-1 (DT:[1064..1067] the) (NN:[1069..1074] tumor)) (VP (VBD:[1075..1078] was) (VP (VBN:[1079..1087] detected) (NP-1 (-NONE-:[1087..1087] *))))))))) (.:[1087..1088] .))) ;sentence 9 Span:1089..1195 ;In the autopsy tissue, the tumor macroscopically occupied the pancreas body ;and was 7 x 6 x 5 cm in size. ;[1116..1121]:malignancy:"tumor" (SENT (S (PP-LOC (IN:[1089..1091] In) (NP (DT:[1092..1095] the) (NN:[1096..1103] autopsy) (NN:[1104..1110] tissue))) (,:[1110..1111] ,) (NP-SBJ (DT:[1112..1115] the) (NN:[1116..1121] tumor)) (VP (VP (ADVP (RB:[1122..1137] macroscopically)) (VBD:[1138..1146] occupied) (NP (DT:[1148..1151] the) (NN:[1152..1160] pancreas) (NN:[1161..1165] body))) (CC:[1166..1169] and) (VP (VBD:[1170..1173] was) (NP-PRD (NP (QP (CD:[1174..1175] 7) (SYM:[1176..1177] x) (CD:[1178..1179] 6) (SYM:[1180..1181] x) (CD:[1182..1183] 5)) (NN:[1184..1186] cm)) (PP (IN:[1187..1189] in) (NP (NN:[1190..1194] size)))))) (.:[1194..1195] .))) ;sentence 10 Span:1196..1286 ;Histopathologic diagnosis of the tumor was poorly differentiated ;adenosquamous carcinoma. ;[1230..1235]:malignancy:"tumor" ;[1240..1285]:malignancy:"poorly differentiated adenosquamous carcinoma" (SENT (S (NP-SBJ (NP (JJ:[1196..1211] Histopathologic) (NN:[1212..1221] diagnosis)) (PP (IN:[1222..1224] of) (NP (DT:[1225..1228] the) (NN:[1230..1235] tumor)))) (VP (VBD:[1236..1239] was) (NP-PRD (ADJP (RB:[1240..1246] poorly) (VBN:[1247..1261] differentiated)) (JJ:[1262..1275] adenosquamous) (NN:[1276..1285] carcinoma))) (.:[1285..1286] .))) ;sentence 11 Span:1287..1400 ;Immunohistochemical staining of the autopsy tissue showed that pancreatic ;cancer cells were positive for G-CSF. ;[1351..1368]:malignancy:"pancreatic cancer" ;[1394..1399]:gene-protein:"G-CSF" (SENT (S (NP-SBJ (NP (JJ:[1287..1306] Immunohistochemical) (NN:[1308..1316] staining)) (PP (IN:[1317..1319] of) (NP (DT:[1320..1323] the) (NN:[1324..1331] autopsy) (NN:[1332..1338] tissue)))) (VP (VBD:[1339..1345] showed) (SBAR (IN:[1346..1350] that) (S (NP-SBJ (JJ:[1351..1361] pancreatic) (NN:[1362..1368] cancer) (NNS:[1369..1374] cells)) (VP (VBD:[1375..1379] were) (ADJP-PRD (JJ:[1380..1388] positive) (PP (IN:[1390..1393] for) (NP (NN:[1394..1399] G-CSF)))))))) (.:[1399..1400] .))) ;sentence 12 Span:1401..1502 ;This is the first case report of G-CSF-positive pancreatic cancer confirmed ;by immunohistochemistry. ;[1434..1466]:malignancy:"G-CSF-positive pancreatic cancer" ;[1434..1439]:gene-protein:"G-CSF" (SENT (S (NP-SBJ (DT:[1401..1405] This)) (VP (VBZ:[1406..1408] is) (NP-PRD (NP (DT:[1409..1412] the) (JJ:[1413..1418] first) (NN:[1419..1423] case) (NN:[1424..1430] report)) (PP (IN:[1431..1433] of) (NP (NP (NML (NN:[1434..1439] G-CSF) (HYPH:[1439..1440] -) (JJ:[1440..1448] positive)) (JJ:[1449..1459] pancreatic) (NN:[1460..1466] cancer)) (VP (VBN:[1468..1477] confirmed) (NP (-NONE-:[1477..1477] *)) (PP (IN:[1478..1480] by) (NP (NN:[1481..1501] immunohistochemistry)))))))) (.:[1501..1502] .))) ;section 13 Span:1506..1550 ;PMID: 9855271 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1506..1510] PMID) (::[1510..1511] :) (CD:[1512..1519] 9855271) (IN:[1520..1521] -LSB-) (NNP:[1521..1527] PubMed) (HYPH:[1528..1529] -) (JJ:[1530..1537] indexed) (IN:[1538..1541] for) (NNP:[1542..1550] MEDLINE-RSB-)))